Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy
Top Cited Papers
Open Access
- 7 July 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (1) , 45-54
- https://doi.org/10.1001/jama.292.1.45
Abstract
Medical therapies for non–ST-segment elevation acute coronary syndromes (ACS) have evolved dramatically over the last decade.1,2 At the same time, trials in high-risk patients have confirmed the benefit of an early invasive treatment strategy with diagnostic angiography and subsequent revascularization, compared with a conservative approach.3,4Keywords
This publication has 9 references indexed in Scilit:
- Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overviewACC Current Journal Review, 2004
- Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled TrialJAMA, 2004
- Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.Circulation, 2003
- ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction—2002: Summary ArticleCirculation, 2002
- Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor TirofibanNew England Journal of Medicine, 2001
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.Journal of Thrombosis and Thrombolysis, 2001
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997